Loading stock data…
$18.04-0.11 (-0.61%)
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology.
Nuvectis Pharma, Inc. in the Healthcare sector is trading at $18.04 with a market capitalization of $718M. Wall Street consensus targets $35.40 (5 analysts), implying a +96.2% move over the next 12 months. The stock is currently 38% below its 52-week high of $29.27, remaining 29.3% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$7.20M↓ | -$6.26M↑ | -$7.62M↑ | -$7.79M↓ | -$6.59M |
| Net Income | -$7.02M↓ | -$6.05M↑ | -$7.31M↑ | -$7.46M↓ | -$6.33M |
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug ca...